Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lavipharm Group

www.lavipharm.com

Latest From Lavipharm Group

Greece prices will fall again with harsh reimbursement list criteria

The Greek government is pushing forth with negative and positive drug lists as a way to cut public pharmaceutical expenditure from about €4.3 billion for 2010 to €3.4 billion in 2011. Public pharma expenditure has fallen already significantly from the €5.1 billion in 2009, where €850 million worth of savings were made in 2010, of which €500 million were the result of drug price cuts.

Turkey

US FDA orders classwide REMS for long-acting opioids

The US FDAis requiring 16 manufacturers of 24 branded and generic opioid medicines to jointly develop a classwide risk evaluation and mitigation strategy (REMS) to reduce deaths and serious injuries resulting from misuse, abuse and overdose.

Neurology

Teva launches transdermal fentanyl in the US

Teva Pharmaceutical Industrieshas received US FDA approval and started shipping its fentanyl transdermal patches, in 25, 50, 75 and 100 μg/hour doses, AB-rated generic versions of Ortho-McNeil's (J&J) Duragesic. Generic fentanyl patches are already available in the US from other companies, including Mylan, Watson, Lavipharm and Actavis. Earlier this year, lots of Watson's and Actavis's versions were separately adversely affected by manufacturing issues. Teva's version is manufactured by Aveva Drug Delivery Systems, a division of Nitto Denko, which Teva describes as one of the world's largest manufacturers of, and pioneer in, drug-in-adhesive transdermal patch technology.

Deals Shaping the Medical Industry (10/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Greece
  • Parent & Subsidiaries
  • Lavipharm Group
  • Senior Management
  • Athanase Lavidas, Chmn. & CEO
  • Contact Info
  • Lavipharm Group
    Phone: (30) 1 669 1100
    Agias Mrinas St.
    Peania Attica
    P.O. Box 59 Athens, 19002
    Greece
Advertisement
Advertisement
UsernamePublicRestriction

Register